Drug intelligence / Profile preview

Pneumococcal conjugate vaccine 10-valent + diphtheria, tetanus, and acellular pertussis vaccine

Development stage
Unknown
Lead developer
GSK
Modality
Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

The "PCV10 + DTaP" refers to the co-administration or fixed-dose combination of two pediatric vaccines: - **PCV10 (pneumococcal conjugate vaccine 10-valent)** protects against infections caused by ten serotypes of *Streptococcus pneumoniae*, including invasive diseases such as meningitis, bacteremia, and pneumonia. It is a protein-polysaccharide conjugate vaccine that stimulates an immune response against the bacterial polysaccharide antigens. - **DTaP (diphtheria, tetanus toxoid and acellular pertussis)** is a combined vaccine that protects against diphtheria (caused by *Corynebacterium diphtheriae*), tetanus (caused by *Clostridium tetani*), and pertussis or whooping cough (caused by *Bordetella pertussis*). The acellular component reduces side effects compared to whole-cell versions. Both vaccines are administered in early childhood as part of routine immunization schedules. They work primarily through induction of protective antibodies targeting bacterial toxins or surface components. These vaccines are often given together but may also be available in fixed-dose combinations depending on regulatory approval in different countries[1][3][5].

Brand names
Synflorix + InfanrixSynflorix + Daptacel
Other names
PCV10/DTaP combination vaccine10-valent pneumococcal conjugate and DTaP combination
02

Targets

Diphtheria toxinCPS (Streptococcus pneumoniae capsular polysaccharide)TT (Tetanus toxoid)

Beyond the preview

Go deeper on Pneumococcal conjugate vaccine 10-valent + diphtheria, tetanus, and acellular pertussis vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pneumococcal conjugate vaccine 10-valent + diphtheria, tetanus, and acellular pertussis vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call